Developer docs
API playgroundTry for free, no card

Search company profiles

Triveni Bio

Full company profile

uuid00009jm

Namestring
Triveni Bio
Legal namestring
Triveni Bio, Inc.
Websiteurl
triveni.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Triveni Bio is a clinical-stage biotechnology company developing antibody therapeutics for immunological and inflammatory (I&I) diseases, founded (corporate launch: October 2023) by Leonard Zon and Tillman Gerngross with headquarters in Watertown, Massachusetts. The company's stated approach combines three pillars: human-genetics-informed target identification, advanced antibody engineering, and novel disease biology. Its lead asset, TRIV-509, is a first-in-class, half-life-extended monoclonal antibody that dually inhibits active kallikreins 5 and 7 (KLK5/7) and is currently in a global Phase 2 proof-of-concept study in moderate-to-severe atopic dermatitis (first patient dosed September 2025). The second clinical asset, TRIV-573, is a second-generation bispecific antibody combining KLK5/7 inhibition with a validated anti-IL-13 mechanism; it entered Phase 1 in May 2026. A third program, TRIV-920, is a first-in-class antibody dually inhibiting active trypsin 1 and 2 for hereditary pancreatitis and is in preclinical development. The pipeline is positioned around an unmet need in atopic dermatitis, where roughly two-thirds of moderate-to-severe patients do not adequately respond to current Th2-focused therapies, and around a rare-disease pancreatitis indication with no approved treatments.

Triveni Bio is pre-revenue and monetises only through future pharmaceutical product sales, with planned distribution via specialty pharmacy and prescriber channels for prescription biologics in I&I. To date the company has been funded entirely by venture capital, raising approximately $272 million across a $92 million Series A (October 2023, Atlas Venture and Cormorant Asset Management co-led), a $115 million Series B (October 2024, Goldman Sachs Alternatives led) and a $65 million Series C (June 2026, Ascenta Capital and Janus Henderson Investors co-led). The investor base includes Atlas Venture, Cormorant, Goldman Sachs Alternatives, Fidelity, Deep Track Capital, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, Ascenta Capital and Janus Henderson. Headcount sits in the 11–50 range and the operating team is led by CEO Vishal Patel (formerly Flagship Pioneering, Novartis, Merck KGaA), CMO Bhaskar Srivastava (formerly Nimbus and Janssen, board-certified dermatologist), CSO and founding employee Jennifer Dovey (formerly Amgen, Biogen, Celgene), and COO Nicholas Scarchilli (formerly Biogen BD, Frankel Group, Raytheon). The company has received external recognition including the Fierce Biotech "Fierce 15" designation in 2025 and an EY Entrepreneur of the Year 2026 finalist nomination for the CEO.

Short descriptiontext

Triveni Bio is a clinical-stage biotechnology company developing genetics-informed antibody therapeutics for immunological and inflammatory diseases, with a Phase 2 lead asset (TRIV-509, KLK5/7 inhibitor) for atopic dermatitis and a preclinical candidate (TRIV-920) for hereditary pancreatitis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, inflammatory disease therapeutics, monoclonal antibody development, atopic dermatitis treatment, genetics-informed drug discovery
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing antibody therapeutics. Revenue will be generated through future pharmaceutical product sales upon regulatory approval.

triveni.bio
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Triveni Bio is a clinical-stage biotechnology company developing antibody-based therapeutics for immunological and inflammatory diseases. Its pipeline includes TRIV-509 (Phase 2, dual KLK5/7 inhibitor for atopic dermatitis), TRIV-573 (Phase 1, bispecific KLK5/7 plus IL-13 inhibitor for atopic dermatitis), and TRIV-920 (preclinical, dual trypsin 1/2 inhibitor for hereditary pancreatitis). Candidates are engineered using human genetics-driven target identification and proprietary antibody engineering to address root-cause disease biology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Triveni Bio is a clinical-stage biotechnology company developing a pipeline of differentiated antibody therapeutics for immunological and inflammatory disorders. The company's portfolio includes TRIV-509 (a first-in-class dual-specific monoclonal antibody targeting KLK5/7 for atopic dermatitis in Phase 2), TRIV-573 (a second-generation bispecific antibody combining KLK5/7 inhibition with anti-IL-13 for atopic dermatitis in Phase 1), and TRIV-920 (a first-in-class trypsin inhibitor for hereditary pancreatitis in preclinical development). All programs leverage the company's genetics-informed approach and advanced antibody engineering capabilities.

Product and service3 records
1TRIV-509
CategoryAntibody therapeutic / core pipeline product
Description

A first-in-class, dual-specific, half-life extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) for the treatment of moderate-to-severe atopic dermatitis, designed to address inflammation, itch, and barrier disruption by targeting protease inhibition.

2TRIV-573
CategoryAntibody therapeutic / core pipeline product
Description

A second-generation, half-life extended bispecific antibody combining dual inhibition of KLK5/7 with a validated anti-IL-13 mechanism, targeting atopic dermatitis by addressing both barrier repair and Th2 inflammation with a single therapeutic.

3TRIV-920
CategoryAntibody therapeutic / core pipeline product
Description

A first-in-class monoclonal antibody with potent dual inhibition of active trypsin 1 and 2, in preclinical development for the treatment of hereditary pancreatitis; targets PRSS1R122H mutation with significant reduction in markers of acute and chronic pancreatic damage in preclinical models.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Rinvoq (upadacitinib, JAK inhibitor) and Skyrizi (risankizumab, IL-23) across multiple inflammatory indications including atopic dermatitis. Represents established competition in the AD market with oral and biologic options.

TypeBroad incumbent
Description

Developer and marketer of Dupixent (dupilumab), the dominant IL-4Rα-targeting biologic for atopic dermatitis and other type-2 inflammatory diseases. Triveni's KLK5/7 and IL-13 programs compete in the same AD market with a differentiated mechanism targeting barrier dysfunction.

TypeEmerging player
Description

Dermatology-focused clinical-stage biotech developing topical and systemic therapies for inflammatory skin diseases including atopic dermatitis. Comparable as a similarly positioned specialty dermatology R&D company targeting the same physician channel.

TypeRegional player
Description

European dermatology-focused specialty pharma with established AD portfolio (e.g., lebrikizumab EU rights). Comparable as a dermatology-specialized company targeting similar patient populations, though primarily serves European markets.

TypeBroad incumbent
Description

Specialty biopharma with marketed dermatology product opzelura (ruxolitinib cream) for atopic dermatitis. Represents commercial-stage competition in the AD topical and broader I&I space.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degraders for immunology and oncology indications. Comparable as a similarly-sized clinical-stage biotech with innovative mechanism of action targeting inflammatory disease.

TypeEmerging player
Description

Clinical-stage biotech developing structure-based drug design across metabolic and inflammatory disease. CMO Bhaskar Srivastava came from Nimbus, and the company represents a comparable small-cap immunology R&D model.

TypeBroad incumbent
Description

Dermatology-focused specialty company marketing nemolizumab (IL-31) for atopic dermatitis and prurigo nodularis. Competes in the same specialty dermatology prescribing channel Triveni plans to target at launch.

TypeDirect peer
Description

Clinical-stage immunology biotech developing antibody therapeutics for I&I indications, including IL-36R antagonist (imsidolimab) and other inflammation targets. Closely comparable as a similarly-sized private/public antibody biotech with overlapping disease focus.

TypeBroad incumbent
Description

Marketer of lebrikizumab, an IL-13-targeted antibody approved for atopic dermatitis. Triveni's TRIV-573 (which combines anti-IL-13 with KLK5/7 inhibition) directly overlaps with this mechanism, making Lilly a key clinical and commercial benchmark.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Triveni Bio

Antibody Therapeuticstriveni.bio

Triveni Bio is a clinical-stage biotechnology company developing genetics-informed antibody therapeutics for immunological and inflammatory diseases, with a Phase 2 lead asset (TRIV-509, KLK5/7 inhibitor) for atopic dermatitis and a preclinical candidate (TRIV-920) for hereditary pancreatitis.

What Triveni Bio does

Triveni Bio is a clinical-stage biotechnology company developing antibody therapeutics for immunological and inflammatory (I&I) diseases, founded (corporate launch: October 2023) by Leonard Zon and Tillman Gerngross with headquarters in Watertown, Massachusetts. The company's stated approach combines three pillars: human-genetics-informed target identification, advanced antibody engineering, and novel disease biology. Its lead asset, TRIV-509, is a first-in-class, half-life-extended monoclonal antibody that dually inhibits active kallikreins 5 and 7 (KLK5/7) and is currently in a global Phase 2 proof-of-concept study in moderate-to-severe atopic dermatitis (first patient dosed September 2025). The second clinical asset, TRIV-573, is a second-generation bispecific antibody combining KLK5/7 inhibition with a validated anti-IL-13 mechanism; it entered Phase 1 in May 2026. A third program, TRIV-920, is a first-in-class antibody dually inhibiting active trypsin 1 and 2 for hereditary pancreatitis and is in preclinical development. The pipeline is positioned around an unmet need in atopic dermatitis, where roughly two-thirds of moderate-to-severe patients do not adequately respond to current Th2-focused therapies, and around a rare-disease pancreatitis indication with no approved treatments.

Triveni Bio is pre-revenue and monetises only through future pharmaceutical product sales, with planned distribution via specialty pharmacy and prescriber channels for prescription biologics in I&I. To date the company has been funded entirely by venture capital, raising approximately $272 million across a $92 million Series A (October 2023, Atlas Venture and Cormorant Asset Management co-led), a $115 million Series B (October 2024, Goldman Sachs Alternatives led) and a $65 million Series C (June 2026, Ascenta Capital and Janus Henderson Investors co-led). The investor base includes Atlas Venture, Cormorant, Goldman Sachs Alternatives, Fidelity, Deep Track Capital, OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, Ascenta Capital and Janus Henderson. Headcount sits in the 11–50 range and the operating team is led by CEO Vishal Patel (formerly Flagship Pioneering, Novartis, Merck KGaA), CMO Bhaskar Srivastava (formerly Nimbus and Janssen, board-certified dermatologist), CSO and founding employee Jennifer Dovey (formerly Amgen, Biogen, Celgene), and COO Nicholas Scarchilli (formerly Biogen BD, Frankel Group, Raytheon). The company has received external recognition including the Fierce Biotech "Fierce 15" designation in 2025 and an EY Entrepreneur of the Year 2026 finalist nomination for the CEO.

Triveni Bio firmographics

Firmographics
Name
Triveni Bio
Legal name
Triveni Bio, Inc.
Website
https://triveni.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Triveni Bio is a clinical-stage biotechnology company developing genetics-informed antibody therapeutics for immunological and inflammatory diseases, with a Phase 2 lead asset (TRIV-509, KLK5/7 inhibitor) for atopic dermatitis and a preclinical candidate (TRIV-920) for hereditary pancreatitis.
Ownership category
akta.pro rank

Triveni Bio industry classification

Industry
Product category
Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Inflammatory disease therapeutics
  • Monoclonal antibody development
  • Atopic dermatitis treatment
  • Genetics-informed drug discovery

Where Triveni Bio is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Triveni Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing antibody therapeutics. Revenue will be generated through future pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Triveni Bio product offering

Product offering

Core offering

Triveni Bio is a clinical-stage biotechnology company developing antibody-based therapeutics for immunological and inflammatory diseases. Its pipeline includes TRIV-509 (Phase 2, dual KLK5/7 inhibitor for atopic dermatitis), TRIV-573 (Phase 1, bispecific KLK5/7 plus IL-13 inhibitor for atopic dermatitis), and TRIV-920 (preclinical, dual trypsin 1/2 inhibitor for hereditary pancreatitis). Candidates are engineered using human genetics-driven target identification and proprietary antibody engineering to address root-cause disease biology.

Product overview

Triveni Bio is a clinical-stage biotechnology company developing a pipeline of differentiated antibody therapeutics for immunological and inflammatory disorders. The company's portfolio includes TRIV-509 (a first-in-class dual-specific monoclonal antibody targeting KLK5/7 for atopic dermatitis in Phase 2), TRIV-573 (a second-generation bispecific antibody combining KLK5/7 inhibition with anti-IL-13 for atopic dermatitis in Phase 1), and TRIV-920 (a first-in-class trypsin inhibitor for hereditary pancreatitis in preclinical development). All programs leverage the company's genetics-informed approach and advanced antibody engineering capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • TRIV-509 A first-in-class, dual-specific, half-life extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) for the treatment of moderate-to-severe atopic dermatitis, designed to address inflammation, itch, and barrier disruption by targeting protease inhibition.
  • TRIV-573 A second-generation, half-life extended bispecific antibody combining dual inhibition of KLK5/7 with a validated anti-IL-13 mechanism, targeting atopic dermatitis by addressing both barrier repair and Th2 inflammation with a single therapeutic.
  • TRIV-920 A first-in-class monoclonal antibody with potent dual inhibition of active trypsin 1 and 2, in preclinical development for the treatment of hereditary pancreatitis; targets PRSS1R122H mutation with significant reduction in markers of acute and chronic pancreatic damage in preclinical models.

Companies that use Triveni Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Triveni Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Triveni Bio partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Triveni Bio competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Rinvoq / Skyrizi): Markets Rinvoq (upadacitinib, JAK inhibitor) and Skyrizi (risankizumab, IL-23) across multiple inflammatory indications including atopic dermatitis. Represents established competition in the AD market with oral and biologic options.
  • Sanofi/Regeneron (Dupixent): Developer and marketer of Dupixent (dupilumab), the dominant IL-4Rα-targeting biologic for atopic dermatitis and other type-2 inflammatory diseases. Triveni's KLK5/7 and IL-13 programs compete in the same AD market with a differentiated mechanism targeting barrier dysfunction.
  • Incyte: Specialty biopharma with marketed dermatology product opzelura (ruxolitinib cream) for atopic dermatitis. Represents commercial-stage competition in the AD topical and broader I&I space.
  • Galderma: Dermatology-focused specialty company marketing nemolizumab (IL-31) for atopic dermatitis and prurigo nodularis. Competes in the same specialty dermatology prescribing channel Triveni plans to target at launch.
  • Eli Lilly (lebrikizumab / Ebglyss): Marketer of lebrikizumab, an IL-13-targeted antibody approved for atopic dermatitis. Triveni's TRIV-573 (which combines anti-IL-13 with KLK5/7 inhibition) directly overlaps with this mechanism, making Lilly a key clinical and commercial benchmark.

Emerging players

  • Arcutis Biotherapeutics: Dermatology-focused clinical-stage biotech developing topical and systemic therapies for inflammatory skin diseases including atopic dermatitis. Comparable as a similarly positioned specialty dermatology R&D company targeting the same physician channel.
  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and oncology indications. Comparable as a similarly-sized clinical-stage biotech with innovative mechanism of action targeting inflammatory disease.
  • Nimbus Therapeutics: Clinical-stage biotech developing structure-based drug design across metabolic and inflammatory disease. CMO Bhaskar Srivastava came from Nimbus, and the company represents a comparable small-cap immunology R&D model.

Regional players

  • Almirall: European dermatology-focused specialty pharma with established AD portfolio (e.g., lebrikizumab EU rights). Comparable as a dermatology-specialized company targeting similar patient populations, though primarily serves European markets.

Direct peers

  • AnaptysBio: Clinical-stage immunology biotech developing antibody therapeutics for I&I indications, including IL-36R antagonist (imsidolimab) and other inflammation targets. Closely comparable as a similarly-sized private/public antibody biotech with overlapping disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Triveni Bio social profiles

Digital presence

Triveni Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Triveni Bio leadership team

Management profile

Number of profiles

Profiles15 records

Triveni Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Triveni Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Triveni Bio

What does Triveni Bio do?

Triveni Bio is a clinical-stage biotechnology company developing antibody-based therapeutics for immunological and inflammatory diseases. Its pipeline includes TRIV-509 (Phase 2, dual KLK5/7 inhibitor for atopic dermatitis), TRIV-573 (Phase 1, bispecific KLK5/7 plus IL-13 inhibitor for atopic dermatitis), and TRIV-920 (preclinical, dual trypsin 1/2 inhibitor for hereditary pancreatitis). Candidates are engineered using human genetics-driven target identification and proprietary antibody engineering to address root-cause disease biology.

Is Triveni Bio a public or private company?

Triveni Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Triveni Bio founded?

Triveni Bio was founded in 2023. It employs 51 to 100 people.

Where is Triveni Bio based?

Triveni Bio is headquartered in Watertown, United States, in the North America region.

How does Triveni Bio make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Triveni Bio's main competitors?

Broad incumbents on record are AbbVie (Rinvoq / Skyrizi), Sanofi/Regeneron (Dupixent), Incyte, Galderma and Eli Lilly (lebrikizumab / Ebglyss). Emerging players are Arcutis Biotherapeutics, Kymera Therapeutics and Nimbus Therapeutics. Almirall is listed as a regional player. AnaptysBio is listed as a direct peer.

Does Triveni Bio have an API?

No public API is recorded for Triveni Bio.

What industry is Triveni Bio in?

Triveni Bio's product category is Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceRamping up: 3 biotechs growing their workforce after series C raisesThree biotechs—Triveni Bio, Ratio Therapeutics, and Basecamp Research—announced series C financing this year and are hiring. Triveni raised $65 million, Ratio $70 million, and Basecamp $140 million, with plans to advance clinical programs and expand operations.pharmaphorumWhich biotechs have raised new VC financing this week?Triveni Bio raised $65 million in a Series C round to fund a phase 2 trial of its TRIV-573 candidate for atopic dermatitis. Cellares added $50 million to its Series D, bringing total funding to $327 million, while HMNC raised $50 million for phase 3 trials of depression drugs. Vedana and Neion Bio also raised $46 million and $23 million respectively.VC News DailyTriveni Bio Raises $65 Million Series C FinancingTriveni Bio, a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, announced a $65 million Series C financing round. The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital and additional existing investors. The funding is intended to support pipeline expansion and continued corporate growth for the company's novel antibody treatments targeting immunological and inflammatory disorders.Pulse 2.0Triveni Bio Raises $65 Million Series C To Expand Clinical Studies For TRIV-573Triveni Bio raised $65 million in Series C funding co-led by Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital, to advance its pipeline of antibody treatments for immunological disorders. The proceeds will fund a Phase 2 proof-of-concept study for TRIV-573 in atopic dermatitis, expected to begin later this year, as well as expanded clinical development following recent first-in-human studies. The company also noted that Evan Rachlin, Managing Partner at Ascenta Capital, has joined Triveni Bio's Board of Directors in connection with the financing.The Pharma LetterTriveni Bio raises $65 million to advance atopic dermatitis bispecificUS biotech company Triveni Bio has raised $65 million in a Series C financing round to advance clinical development of TRIV-573, its bispecific antibody candidate for moderate-to-severe atopic dermatitis. The Watertown, Massachusetts-based company's round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital and existing backers. The funding will support progression of the candidate through clinical development stages.Endpoints NewsTriveni Bio rais­es $65M ahead of up­com­ing read­outs on eczema drugsTriveni Bio announced a $65 million Series C funding round after its second asset for eczema entered clinical studies last month; the round was co-led by undisclosed investors.PR NewswireTriveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthTriveni Bio Inc., a clinical-stage biotechnology company focused on immunological and inflammatory disorders, announced the closing of a $65 million Series C financing round co-led by Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital and existing investors. The funding will support Phase 2 clinical proof-of-concept studies for TRIV-573, the company's bispecific antibody targeting IL-13 and KLK5/7 for atopic dermatitis, with the trial expected to initiate later this year. As part of the financing, Ascenta Capital co-founder Evan Rachlin joined Triveni Bio's Board of Directors, and CEO Vishal Patel was named a finalist for the Ernst & Young Entrepreneur Of The Year 2026 award.TechStartupsVenture Capital & Startup Funding Roundup, June 17, 2026Ten venture capital rounds totaling roughly $798.5 million were announced on June 17, 2026, with the largest check going to Odyssey's $310 million Series B. The funding concentrated in AI infrastructure, cybersecurity, and regulated financial systems, reflecting investor preference for deployment tools over consumer AI.YahooTriveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthTriveni Bio raised $65 million in a Series C round co-led by Ascenta Capital and Janus Henderson Investors. The funds will support a Phase 2 proof-of-concept trial for its bispecific TRIV-573 targeting IL-13 and KLK5/7 in atopic dermatitis, expected to start later this year.Venture Capital Access OnlineTriveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthTriveni Bio raised $65 million in a Series C round co-led by Ascenta Capital and Janus Henderson Investors. The funds will support a Phase 2 proof-of-concept trial for its bispecific antibody TRIV-573 in atopic dermatitis, expected to start later this year. Evan Rachlin joined the board.